New developments surrounding the safety of bisphosphonates

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 15, Issue 6, 2008, Pages 508-513

  Arum, Seth M ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Atrial fibrillation; Bisphosphonates; Osteonecrosis of the jaw; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ALBERS SCHOENBERG DISEASE; AWARENESS; BONE NECROSIS; BONE TURNOVER; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HUMAN; INFORMED CONSENT; JAW DISEASE; MUSCULOSKELETAL PAIN; OSTEOPOROSIS; PATIENT DECISION MAKING; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT PLANNING;

ATRIAL FIBRILLATION; BONE DISEASES, METABOLIC; CLINICAL PROTOCOLS; DIPHOSPHONATES; GASTROINTESTINAL DISEASES; HUMANS; JAW DISEASES; MUSCULOSKELETAL SYSTEM; OSTEONECROSIS; PAIN;

EID: 56749105613     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e3283184017     Document Type: Review

References (68)

1. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348:1535-1541.
2. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 1998; 250:2077-2082.
3. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 1999; 282:1344-1352.
4. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344:333-340.
5. Chestnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19:1241-1249.
6. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postemenopausal osteoporosis. N Engl J Med 2007; 356:1809-1822. Landmark trial proving fracture efficacy of zoledronic acid. It also introduced the possible connection between bisphosphonates and atrial fibrillation.
7. Schiller JH, Rasmussen P, Benson AB, et al. Maintenance etidronate in the prevention of malignancy-associated hypercalcemia. Arch Intern Med 1987; 147:963-966.
8. Reid IR, King AR, Alexander CJ, Ibbertson HK. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1- bisphosphonate (APD). Lancet 1988; 1:143-146.
9. Lufkin EG, Argueta R, Whitaker MD, et al. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos Int 1994; 4:320-322.
10. Manconi G, Porro GB. Multiple ulcerative esophagitis caused by alendronate. Am J Gastroenterol 1995; 90:1889-1890.
11. de Groen PC, Lubbe DF, Hirsch U, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996; 335:1016-1021.
12. Kaye PS. Gastric hemorrhage and ulceration in hiatal hernia sac associated with alendronate. Dig Dis Sci 1999; 44:903-904.
13. Lanza FL, Hunt RH, Thomson ABR, et al. Endoscopic comparison of esophageal and grastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 2000; 119:631-638.
14. Lanza FL, Schwartz H, Sahba B, et al. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am J Gastroenterol 2000; 95:3112-3117.
15. Cryer B, Bauer DC. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 2002; 77:1031-1043.
16. Graham DY, Malaty HM, Goodgame R. Primary amino-bisphosphonates: a new class of gastrotoxic drugs - comparison of alendronate and aspirin. Am J Gastroenterol 1997; 92:1322-1325.
17. Tremaine WJ, Khosla S. Editorial: bisphosphonates and the upper gastrointestinal tract - skeletal gain without visceral pain? Mayo Clin Proc 2002; 77:1029-1030.
18. Fosamax package insert. http://www.merck.com/product/usa/pi_circulars/f/ fosamax/fosamax_pi.pdf
19. Adachi JD, Adami S, Miller PD, et al. Tolerability of risedronate in postmenopausal women intolerant of alendronate. Aging 2001; 13:344-346.
20. Miller PD, Woodson G, Licata AA, et al. Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. Clin Ther 2000; 22:1433-1442.
21. Epstein S, Cryer B, Ragi S, et al. Disintegration/dissolution profiles of copies of Fosamax (alendronate). Curr Med Res Opin 2003; 19:781-789.
22. Halkin H, Dushenat M, Silverman B, et al. Brand versus generic alendronate: gastrointestincal effects measured by resource utilization. Ann Pharmacother 2007; 47:23-34. Recent epidemiologic study comparing gastrointestinal effects of Fosamax with generic alendronate.
23. Watts NB, Marciani RD. Osteonecrosis of the jaw. South Med J 2008; 101:160-165.
24. Schwartz HC. Osteonecrosis of the jaws: a complication of cancer chemotherapy. Head Neck Surg 1982; 4:251-253.
25. Khosla S, Burr D, Cauley J, et al. Editorial: bisphosphonate- associated osteonecrosis of the jaw - report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22:1479-1491. Recent task force report on ONJ with consensus definitions, literature review, and management recommendations.
26. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61:1115-1118.
27. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003; 21:4253-4254.
28. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62:527-534.
29. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63:1567-1575.
30. Woo S, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144:753-761.
31. Rizzoli R, Burlet N, Cahall D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 2008; 42:841-847. Recent review with a good overview on the pathophysiology of ONJ.
32. Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353:99-100.
33. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphophonates: incidence and risk factors. J Clin Oncol 2005; 23:8580-8587.
34. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007; 65:415-423. Survery study showing a surprisingly high prevalence of ONJ with oral bisphosphonates.
35. Sambrook P, Olver I, Goss A. Bisphosphonates and osteonecrosis of the jaw. Aust Fam Physician 2006; 35:801-803.
36. Felsenberg D, Hoffmeister B, Michael Amling M. Associations with bisphosphonate therapy. Kiefernekrosen Deutsches Arzteblatt 2006; 46:A3078-A3080.
37. Polizzotto MN, Cousins V, Schwarer AP. Bisphosphonate-associated osteonecrosis of the auditory canal. Br J Haematol 2006; 132:114.
38. Etminan M, Aminzadeh K, Matthew IR, Brophy JM. Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case-control study. J Rheumatol 2008; 35:691-695.
39. Marx RE, Cillo JE, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention and treatment. J Oral Maxillofac Surg 2007; 65:2397-2410. A controversial study outlining recommendations to use serum CTX to predict the risk of ONJ after a dental procedure and to guide bisphosphonate management surrounding such procedures.
40. Khosla S, Burr D, Cauley J, et al. Letter to the editor: oral bisphosphonate-induced osteonecrosis - risk factors, prediction of risk using serum CTX testing, prevention and treatment. J Oral Maxillofac Surg 2008; 66:1321-1322.
41. Vescovi P, Merigo E, Manfredi M, et al. Nd:YAG Laser biostimulation in the treatment of bisphosphonate-associated osteonecrosis of the jaw: clinical experience in 28 cases. Photomed Laser Surg 2008; 26:37-46. Report of successful use of low-level laser therapy to treat ONJ.
42. Harper RP, Fung E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg 2007; 65:573-580. Report of successful use of teriparitide for the treatment of ONJ.
43. Black D, Eriksen E, Sellmeyer D. The authors reply: yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med 2007; 357:714-715.
44. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med 2007; 356:1895-1896. Report of atrial fibrillation data from the Fracture Intervention Trial.
45. Karam R, Camm J, McClung M. Correspondence: yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med 2007; 357:712-713. Report of atrial fibrillation data from phase three trials with risedronate.
46. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357:1799-1809. Large RCT of zoledronic acid showing no difference in atrial fibrillation when compared with placebo.
47. Sørensen HT, Christensen S, Mehnert F, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 2008; 336:813-816. Epidemiologic study showing no association between bisphosphonate use and atrial arrhythmias.
48. Heckbert SR, Li G, Cumming SR, et al. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008; 168:826-831. Epidemiologic study showing an association between bisphosphonate use and atrial fibrillation.
49. Cauley JA, Ensrud KE. Considering competing risks. . .not all black and white. Arch Intern Med 2008; 168:793-795.
50. Wysowski DK, Chang JT. Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med 2005; 165:346-347.
51. Bock O, Boerst H, Thomasius FE, et al. Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention. J Musculoskelet Neuronal Interact 2007; 7:144-148. Retrospective study showing a surprisingly high frequency of significant musculoskeletal complaints with weekly oral bisphosphonates and a suggestion that it can be prevented by starting with daily dosing.
52. Food and Drug Asministration. Information on bisphosphonatess (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa). http://www.fda.gov/cder/drug/infopage/bisphosphonates/ default.htm. Recent FDA alert aiming to renew the awareness of severe musculoskeletal pain as a potential side effect of oral bisphosphonates.
53. Ott SM. Editorial: long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005; 90:1897-1899.
54. Mashiba T, Hirano T, Turner CH, et al. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000; 15:613-620.
55. Mashiba T, Turner CH, Hirano T, et al. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biochemical properties in clinically relevant skeletal sites in beagles. Bone 2001; 28:524-531.
56. Komatsubara S, Mori S, Mashiba T, et al. Long-term treatment of icadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebrae. J Bone Miner Res 2003; 18:512-520.
57. Komatsubara S, Mori S, Mashiba T, et al. Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res 2004; 19:999-1005.
58. Sobelman OS, Gibeling JC, Stover SM, et al. Do microcracks decrease or increase fatigue resistance in cortical bone? J Biomec 2004; 37:1295-1303.
59. Whyte MP, Wenkert D, Clements KL, et al. Bisphosphonate-induced osteopetrosis. N Engl J Med 2003; 349:457-463.
60. Odvina CV, Zerwekh JE, Rao S, et al. Severerly suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90:1294-1301.
61. Schneider JP. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics 2006; 61:31-33.
62. Armamento-Villareal R, Napoli N, Panwar V, Novack D. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med 2006; 355:2048-2050.
63. Cheung RKH, Leung KK, Lee KC, Chow TC. Sequential nontraumatic femoral shaft fractures in a patient on long-term alendronate. Hong Kong Med J 2007; 13:485-489.
64. Kwek EBK, Goh SK, Koh JSB, et al. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 2008; 39:224-231. Larger series of 17 patients with subtrochanteric fractures after long-term alendronate use, including one patient who was switched to risedronate after 4 years on alendronate therapy.
65. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008; 358:1304-1306. Case series describing a unique radiographic pattern of femoral shaft fractures in patients on long-term alendroate therapy.
66. Neviaser AS, Lane JM, Lenart BA, et al. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008; 22:346-350. Recent retrospective study showing that alendronate is a significant risk factor for developing femoral shaft fractures with a unique radiographic pattern. It also confirmed that patients with this specific fracture pattern took alendronate for significantly longer periods of time.
67. Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrin Metab 2008; 93:2948-2952.
68. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment. The Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 2996:2927-2938.